Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
13.10 x 1 15.09 x 3
Pre-market by (Cboe BZX)
13.73 +0.02 (+0.15%) 03/24/25 [NASDAQ]
13.10 x 1 15.09 x 3
Pre-market 13.73 unch (unch) 16:00 ET
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
13.39
Day High
13.97
Open 13.76
Previous Close 13.71 13.71
Volume 1,018,800 1,018,800
Avg Vol 1,972,750 1,972,750
Stochastic %K 48.48% 48.48%
Weighted Alpha -36.77 -36.77
5-Day Change +0.69 (+5.29%) +0.69 (+5.29%)
52-Week Range 12.06 - 25.07 12.06 - 25.07
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,181,110
  • Shares Outstanding, K 86,024
  • Annual Sales, $ 23,680 K
  • Annual Income, $ -318,760 K
  • EBIT $ -339 M
  • EBITDA $ -352 M
  • 60-Month Beta 0.92
  • Price/Sales 49.81
  • Price/Cash Flow N/A
  • Price/Book 4.18

Options Overview Details

View History
  • Implied Volatility 72.11% ( -0.72%)
  • Historical Volatility 55.75%
  • IV Percentile 75%
  • IV Rank 46.82%
  • IV High 125.49% on 10/30/24
  • IV Low 25.12% on 06/04/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 275
  • Volume Avg (30-Day) 1,204
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 23,963
  • Open Int (30-Day) 33,599

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.02
  • Number of Estimates 7
  • High Estimate -0.85
  • Low Estimate -1.13
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.26 +11.99%
on 03/11/25
Period Open: 15.67
16.50 -16.79%
on 03/03/25
-1.94 (-12.38%)
since 02/24/25
3-Month
12.06 +13.85%
on 01/14/25
Period Open: 13.07
16.95 -19.00%
on 02/21/25
+0.66 (+5.05%)
since 12/24/24
52-Week
12.06 +13.85%
on 01/14/25
Period Open: 22.58
25.07 -45.23%
on 07/26/24
-8.85 (-39.19%)
since 03/22/24

Most Recent Stories

More News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX : 13.73 (+0.15%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 13.73 (+0.15%)
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

SNDX : 13.73 (+0.15%)
Syndax Announces Participation in March Investor Conferences

SNDX : 13.73 (+0.15%)
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

SNDX : 13.73 (+0.15%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.75 (+0.15%)
JNJ : 163.29 (-0.21%)
VRTX : 511.74 (+1.70%)
SNDX : 13.73 (+0.15%)
ABBV : 209.17 (-0.40%)
GERN : 1.7500 (-3.85%)
RHHBY : 42.9100 (-1.81%)
PFE : 26.14 (-0.53%)
NTLA : 9.31 (+3.44%)
BMY : 61.05 (-0.03%)
BIIB : 141.60 (+0.50%)
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

The recent advancements in their pipelines imply high growth potential in the coming years.

ZVRA : 8.21 (+2.50%)
RPRX : 33.75 (+0.15%)
SNDX : 13.73 (+0.15%)
INCY : 62.78 (+1.39%)
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.6293 (-0.13%)
IOVA : 3.63 (+2.54%)
SNDX : 13.73 (+0.15%)
ONC.TO : 0.89 (-2.20%)
IBRX : 2.85 (+5.17%)
SWTX : 48.51 (-2.77%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.6293 (-0.13%)
IOVA : 3.63 (+2.54%)
SNDX : 13.73 (+0.15%)
ONC.TO : 0.89 (-2.20%)
IBRX : 2.85 (+5.17%)
SWTX : 48.51 (-2.77%)
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 13.73 (+0.15%)
1 ‘Strong Buy’ Stock to Load up on for Potential 76% Upside in 2025

Investors should snag this ‘Strong Buy’ stock before market jitters fade and an over-76% rally in 2025 takes shape.

$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)
Datadog to Present at Upcoming Investor Conference

New York, New York--(Newsfile Corp. - February 25, 2025) - Datadog, Inc. (NASDAQ: DDOG), the monitoring and security platform for cloud applications, today announced that management will present at the...

DDOG : 110.17 (+4.89%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The iconic growth investor made some interesting moves to kick off the new market week.

IRDM : 28.19 (+1.95%)
DDOG : 110.17 (+4.89%)
AMZN : 203.26 (+3.59%)
Wall Street Forecasts 71% Upside for This Under-the-Radar Tech Stock. Is It A Buy Now?

Datadog is growing rapidly, earning a “Strong Buy” rating on Wall Street.

MSFT : 393.08 (+0.47%)
GOOGL : 167.68 (+2.25%)
$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)
ORCL : 154.87 (+1.73%)
AMZN : 203.26 (+3.59%)
1 Glorious Growth Stock Down 33% to Buy Hand Over Fist, According to Wall Street

Even though major U.S. stock market indexes like the S&P 500 and the Nasdaq Composite continue climbing to new highs, not every individual stock is following along.

COMP : 9.61 (+2.34%)
DDOG : 110.17 (+4.89%)
Datadog in the Doghouse After Disappointing Forecast. Is It Time to Buy the Stock on the Dip?

Shares of Datadog (NASDAQ: DDOG) are down 19% since the cloud security platform provider issued a weaker-than-expected 2025 outlook with slower revenue growth and higher expenses.

DDOG : 110.17 (+4.89%)
Datadog Opens Registration for Its 2025 DASH Conference

The annual conference will take place in New York on June 10-11 and feature speaking sessions from customers like Redfin, Thales IFE, Toyota and VolkswagenNew York, New York--(Newsfile Corp. - February...

DDOG : 110.17 (+4.89%)
Is Datadog Stock a Buy Now?

Datadog (NASDAQ: DDOG) stock experienced a setback following the release of the company's fourth-quarter 2024 results on Feb. 13, despite delivering better-than-expected numbers, as a slowdown in customer...

DDOG : 110.17 (+4.89%)
DDOG Q4 Results Shine, '25 View Disappoints: How to Play the Stock

Datadog DDOG delivered strong fourth-quarter 2024 results that exceeded the Zacks Consensus Estimate, but shares tumbled approximately 9% as the company's conservative 2025 guidance overshadowed the impressive...

MSFT : 393.08 (+0.47%)
GOOGL : 167.68 (+2.25%)
DDOG : 110.17 (+4.89%)
AMZN : 203.26 (+3.59%)
2 No-Brainer Stocks to Buy Now With $250 Before They Soar in 2025, According to Wall Street

The S&P 500 (SNPINDEX: ^GSPC) has advanced 21% in the last year, and many stocks now trade at expensive valuations. However, most Wall Street analysts still see buying opportunities in Datadog (NASDAQ:...

TTD : 59.34 (+5.38%)
$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)
1 ‘Strong Buy’ Stock to Load up on for Potential 76% Upside in 2025

Investors should snag this ‘Strong Buy’ stock before market jitters fade and an over-76% rally in 2025 takes shape.

$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)
Datadog to Present at Upcoming Investor Conference

New York, New York--(Newsfile Corp. - February 25, 2025) - Datadog, Inc. (NASDAQ: DDOG), the monitoring and security platform for cloud applications, today announced that management will present at the...

DDOG : 110.17 (+4.89%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The iconic growth investor made some interesting moves to kick off the new market week.

IRDM : 28.19 (+1.95%)
DDOG : 110.17 (+4.89%)
AMZN : 203.26 (+3.59%)
Wall Street Forecasts 71% Upside for This Under-the-Radar Tech Stock. Is It A Buy Now?

Datadog is growing rapidly, earning a “Strong Buy” rating on Wall Street.

MSFT : 393.08 (+0.47%)
GOOGL : 167.68 (+2.25%)
$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)
ORCL : 154.87 (+1.73%)
AMZN : 203.26 (+3.59%)
1 Glorious Growth Stock Down 33% to Buy Hand Over Fist, According to Wall Street

Even though major U.S. stock market indexes like the S&P 500 and the Nasdaq Composite continue climbing to new highs, not every individual stock is following along.

COMP : 9.61 (+2.34%)
DDOG : 110.17 (+4.89%)
Datadog in the Doghouse After Disappointing Forecast. Is It Time to Buy the Stock on the Dip?

Shares of Datadog (NASDAQ: DDOG) are down 19% since the cloud security platform provider issued a weaker-than-expected 2025 outlook with slower revenue growth and higher expenses.

DDOG : 110.17 (+4.89%)
Datadog Opens Registration for Its 2025 DASH Conference

The annual conference will take place in New York on June 10-11 and feature speaking sessions from customers like Redfin, Thales IFE, Toyota and VolkswagenNew York, New York--(Newsfile Corp. - February...

DDOG : 110.17 (+4.89%)
Is Datadog Stock a Buy Now?

Datadog (NASDAQ: DDOG) stock experienced a setback following the release of the company's fourth-quarter 2024 results on Feb. 13, despite delivering better-than-expected numbers, as a slowdown in customer...

DDOG : 110.17 (+4.89%)
DDOG Q4 Results Shine, '25 View Disappoints: How to Play the Stock

Datadog DDOG delivered strong fourth-quarter 2024 results that exceeded the Zacks Consensus Estimate, but shares tumbled approximately 9% as the company's conservative 2025 guidance overshadowed the impressive...

MSFT : 393.08 (+0.47%)
GOOGL : 167.68 (+2.25%)
DDOG : 110.17 (+4.89%)
AMZN : 203.26 (+3.59%)
2 No-Brainer Stocks to Buy Now With $250 Before They Soar in 2025, According to Wall Street

The S&P 500 (SNPINDEX: ^GSPC) has advanced 21% in the last year, and many stocks now trade at expensive valuations. However, most Wall Street analysts still see buying opportunities in Datadog (NASDAQ:...

TTD : 59.34 (+5.38%)
$SPX : 5,767.57 (+1.76%)
DDOG : 110.17 (+4.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 14.59
2nd Resistance Point 14.28
1st Resistance Point 14.01
Last Price 13.73
1st Support Level 13.42
2nd Support Level 13.11
3rd Support Level 12.84

See More

52-Week High 25.07
Fibonacci 61.8% 20.10
Fibonacci 50% 18.57
Fibonacci 38.2% 17.03
Last Price 13.73
52-Week Low 12.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.